baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

HSBC Knock-Out REGN/ DE000TT6X0N4 /

26/07/2024 21:35:19	Chg.+1.220	Bid21:59:05	Ask21:59:05	Underlying	Strike price	Expiration date	Option type
61.790EUR	+2.01%	- Bid Size: -	- Ask Size: -	Regeneron Pharmaceut...	409.6453 USD	31/12/2078	Call

GlobeNewswire 30/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 28/06 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...

GlobeNewswire 27/06 Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...

GlobeNewswire 26/06 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...

GlobeNewswire 26/06 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...

GlobeNewswire 22/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 18/06 Kriya Appoints Katherine Eade as Chief Legal Officer

GlobeNewswire 18/06 Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD ...

GlobeNewswire 16/06 Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...

GlobeNewswire 13/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 11/06 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...

GlobeNewswire 05/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 04/06 Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 03/06 FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroG...

GlobeNewswire 31/05 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 31/05 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewswire 31/05 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 31/05 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...

GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 28/05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 23/05 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...

GlobeNewswire 22/05 Invivyd Elects Two New Independent Members to its Board of Directors

GlobeNewswire 21/05 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire 20/05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 20/05 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

HSBC Knock-Out REGN/ DE000TT6X0N4 /

If you wish to receive reply to your feedback, please provide your email address.